Biotech Addition emerges with $100M from the Gates Foundation to develop next-generation gene therapies for chronic and rare diseases with a new approach The Silicon Review.

COLONIAL HEIGHTS, Va. -- Sickle cell disease dramatically shortens the lifespan of the nearly 100,000 Americans — mostly African Americans — and 2 million people worldwide. The inherited, incurable ...

Myriad Genetics is a leading molecular diagnostic company that focuses on developing and marketing predictive, personalized, and prognostic medicine tests. The company's financial metrics show ...

Addition Therapeutics came out of stealth mode to highlight its Precise RNA-Mediated Insertion of Transgenes (PRINT) gene therapy platform. The system is based on research of retrotransposons by ...

SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell ...

Julie Kanter, M.D., director of the UAB Adult Sickle Cell Clinic, says patients treated with this therapy are beginning to show signs of producing stable amounts of normal red blood cells containing ...

Genetics is the study of genes and how they influence characteristics and health. Through a variety of technological methods, environmental factors, and lifestyle choices, it is possible to alter some ...

Almost 20 years following the completion of the Human Genome Project — a historic scientific achievement that resulted in generating the first sequence of the human genome — gene therapy is no longer ...

Please provide your email address to receive an email when new articles are posted on . One specialist argued that, in the future, gene therapy technologies will be the favored option for wet AMD.